Cargando…

Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients

The BRCA1/2 germline and/or somatic pathogenic variants (PVs) are key players in the hereditary predisposition and therapeutic response for breast, ovarian and, more recently, pancreatic and prostate cancers. Aberrations in other genes involved in homologous recombination and DNA damage response (DD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalmasso, Bruna, Puccini, Alberto, Catalano, Fabio, Borea, Roberto, Iaia, Maria Laura, Bruno, William, Fornarini, Giuseppe, Sciallero, Stefania, Rebuzzi, Sara Elena, Ghiorzo, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099822/ https://www.ncbi.nlm.nih.gov/pubmed/35563100 http://dx.doi.org/10.3390/ijms23094709

Ejemplares similares

Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients
por: Puccini, Alberto, et al.
Publicado: (2022)

Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
por: Catalano, Fabio, et al.
Publicado: (2022)

Long Non-Coding RNAs and Metabolic Rewiring in Pancreatic Cancer
por: Dalmasso, Bruna, et al.
Publicado: (2023)

Functional analysis of a CDKN2A 5’UTR germline variant associated with pancreatic cancer development
por: Bruno, William, et al.
Publicado: (2017)

The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives
por: Gandini, Annalice, et al.
Publicado: (2023)

Pancreatic Cancer: Beyond Brca Mutations
por: Ricci, Vincenzo, et al.
Publicado: (2022)

Pancreatic Cancer: BRCA Targeted Therapy and Beyond
por: Keane, Fergus, et al.
Publicado: (2023)

Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives
por: Zimmer, Kai, et al.
Publicado: (2021)

Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations
por: Chahla, Elie, et al.
Publicado: (2016)

Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance
por: Martínez-Galán, Joaquina, et al.
Publicado: (2021)

Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers
por: Germani, Aldo, et al.
Publicado: (2020)

Beyond the Prognostic Value of 2-[(18)F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management
por: Borea, Roberto, et al.
Publicado: (2022)

Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer
por: Hu, Yunlong, et al.
Publicado: (2020)

Pancreatic Cancer: From Genetic Mechanisms to Translational Challenges
por: Pastorino, Lorenza, et al.
Publicado: (2023)

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer
por: Voutsadakis, Ioannis A., et al.
Publicado: (2023)

Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients
por: Espinel, Whitney, et al.
Publicado: (2022)

The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study
por: Bauckneht, Matteo, et al.
Publicado: (2020)

Clinical significance of large rearrangements in BRCA1 and BRCA2
por: Judkins, Thaddeus, et al.
Publicado: (2012)

Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2
por: Barbosa, Ana, et al.
Publicado: (2020)

BRCA1 and BRCA2 mutations in central and southern Italian patients
por: Ottini, Laura, et al.
Publicado: (2000)

Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations
por: Bruno, William, et al.
Publicado: (2017)

Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations
por: Bruno, William, et al.
Publicado: (2018)

BRCA1, BRCA2 and their possible function in DNA damage response
por: Kote-Jarai, Z, et al.
Publicado: (1999)

Clinical significance of variants of unknown significances in BRCA genes
por: Choi, Min Chul
Publicado: (2019)

Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
por: Samuel, David, et al.
Publicado: (2022)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival
por: Boursi, Ben, et al.
Publicado: (2023)

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
por: Seeber, Andreas, et al.
Publicado: (2020)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)

Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
por: Catalano, Fabio, et al.
Publicado: (2023)

BRCA1 and BRCA2 Gene Mutations in Breast/Ovarian Cancer Patients from Central and Southern Italy
por: Ottini, Laura, et al.
Publicado: (1999)

Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry
por: Bruno, William, et al.
Publicado: (2016)

The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
por: Cavanagh, Helen, et al.
Publicado: (2015)

Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance
por: Ozgencil, Meryem, et al.
Publicado: (2021)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma
por: Mai, Phuong L., et al.
Publicado: (2009)

BRCA1 in the DNA damage response and at telomeres
por: Rosen, Eliot M.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3cotg152nuiqdqifjraujh99ra